

In the article "Suppression of erythro-megakaryocytopoiesis and the induction of reversible thrombocytopenia in mice transgenic for the thymidine kinase gene targeted by platelet growth glycoprotein IIb promoter" by D. Tronik-Le Roux, V. Roullot, A. Schweitzer, R. Berthier, and G. Marguerie (June 1995, 181:2141–2151), some data were left out of Tables 1 and 3. The complete tables appear below.

Table 1. Effect of GCV Treatment on Blood Cell Counts

	Control mouse			α IIbtk mouse		
	D0	D10	D23	D0	D10	D23
Erythrocytes ($\times 10^{12}$)	10.91 \pm 2.3	10.93 \pm 1.13	10.88 \pm 0.5	10.69 \pm 3.053	9.23 \pm 0.59	3.12 \pm 0.88
Leukocytes ($\times 10^9$)	10.19 \pm 1.5	12.33 \pm 4.0	13.00 \pm 1.0	8.33 \pm 4.27	8.15 \pm 1.65	13.59 \pm 14.08
Platelets ($\times 10^{12}$)	0.80 \pm 0.09	0.93 \pm 0.18	0.77 \pm 0.14	0.73 \pm 0.12	0.045 \pm 0.012	0.02 \pm 0.007

Mean peripheral blood cell counts (\pm SD) of control and transgenic α IIbtk mice ($n = 5$) before (D0), 10 d (D10), or 23 d (D23) of GCV (0.05 mg/g per d) treatment. The counts shown are per liter of blood volume.

Table 3. Number of Monopotent and Mixed Myeloid Colonies from BM cells of Control and α IIbtk Mice Treated with GCV

	GM-CFC	BFU-E	MK	BFU-E-MK	GEM + GEMK + GMMK	GEMMK
Experiment 1						
Control	64 \pm 11.5	12 \pm 1.8	4 \pm 1.7	4.5 \pm 1.1	8.5 \pm 3.6	2.2 \pm 0.8
α IIbtk	61 \pm 3.3	0.6 \pm 0.5	1.4 \pm 0.9	0.6 \pm 0.9	1.6 \pm 1.5	0.4 \pm 0.5
Experiment 2						
Control	71 \pm 8.5	8 \pm 3.3	9 \pm 2.2	2.2 \pm 0.8	4 \pm 1.6	2 \pm 1
α IIbtk	59 \pm 7.4	0.75 \pm 0.5	0.25 \pm 0.5	0	0	0

Marrow cells (5×10^4 /ml per dish) from control and α IIbtk mice treated with GCV (1 mg/d for 10 d) were obtained by femoral aspiration and plated in 1 ml of culture medium as described in Materials and Methods. The number of colonies was the mean SD of five identical dishes. Mixed colonies consisted of bilineage BFU-E-MK (erythroid and megakaryocytic), trilineage GEM (granulocytic erythroid macrophagic), GEMK (granulocytic erythroid megakaryocytic), GMMK (granulocytic macrophagic megakaryocytic), and multipotent GEMMK (granulocytic erythroid macrophagic and megakaryocytic).